Management of Antiplatelet Therapy

Introduction to Antiplatelet Therapy

• The American College of Cardiology (ACC) and American Heart Association (AHA) recommend continuing aspirin at a dosage of 75-162 mg daily indefinitely in patients with coronary stents, unless contraindicated, to minimize the risk of stent thrombosis, which increases up to sevenfold with premature discontinuation of antiplatelet therapy 1
• Maintaining antiplatelet therapy is critical for patients with heart stents, and the risk of stent thrombosis from antiplatelet discontinuation outweighs the bleeding risk, even in patients with anemia 2

Aspirin Therapy

• Low-dose aspirin (81 mg) is recommended to minimize bleeding risk while providing necessary antiplatelet effect, and it is reasonable to continue aspirin indefinitely after renal transplantation in patients with known coronary artery disease (CAD), with a strength of evidence classified as high by the ACC 1, 3

Clopidogrel Therapy

• Clopidogrel is effective in patients with a history of coronary stent placement, with a magnitude of platelet inhibition comparable to non-dialysis patients, although specific data on dialysis patients is limited 1

Bleeding Risk Management

• Proton pump inhibitors can be used to reduce gastrointestinal bleeding risk in patients on dual antiplatelet therapy 2
• Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided as they can increase bleeding risk in patients on antiplatelet therapy 1

Monitoring and Follow-up

• Hemoglobin levels should be checked every 2-3 days initially in patients with anemia, and antiplatelet strategy should be reassessed if hemoglobin drops below 7.0 g/dL 1
• If active bleeding develops, clopidogrel can be temporarily held while maintaining aspirin, but both medications should never be discontinued simultaneously if the stent was placed within the past year 1

Timing of Antiplatelet Therapy

• Dual antiplatelet therapy is essential for the first 12 months after stent placement to prevent stent thrombosis, with a strength of evidence classified as high 1, 4, 5, 6
• Aspirin should be maintained throughout most procedures and should never be discontinued for at least 6-12 months after drug-eluting stent placement due to the high risk of stent thrombosis, as recommended by the British Journal of Anaesthesia guidelines 5
• The following patients should continue dual antiplatelet therapy: those with drug-eluting stents placed within the past 6-12 months, a history of stent thrombosis, multiple stents, long stents, or bifurcation stents, diabetic patients, low ejection fraction, or incomplete revascularization, as recommended by the British Journal of Anaesthesia and Circulation guidelines 5, 6
• For minor bleeding risk procedures, both aspirin and clopidogrel should be maintained, while for intermediate bleeding risk procedures, aspirin should be maintained and clopidogrel may be temporarily stopped for 5 days if more than 6 months post-drug-eluting stent placement, as stated in the British Journal of Anaesthesia guidelines 5
• A multidisciplinary team meeting should occur before any antiplatelet interruption to assess individual thrombotic risk, evaluate procedure-specific bleeding risk, determine optimal perioperative antiplatelet management, and document the consensus plan in the medical record, as recommended by the British Journal of Anaesthesia guidelines 5
• Aspirin should be resumed within 24-48 hours after procedure unless absolutely contraindicated, and a loading dose (325 mg) should be considered when restarting aspirin after interruption, as recommended by the British Journal of Anaesthesia guidelines 5